Alvotech Warrant
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more
Alvotech Warrant (ALVOW) - Total Liabilities
Latest total liabilities as of September 2025: $1.59 Billion USD
Based on the latest financial reports, Alvotech Warrant (ALVOW) has total liabilities worth $1.59 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alvotech Warrant - Total Liabilities Trend (2020–2024)
This chart illustrates how Alvotech Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alvotech Warrant Competitors by Total Liabilities
The table below lists competitors of Alvotech Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
USA | $6.90 Million |
|
Melcor Real Estate Investment Trust
TO:MR-UN
|
Canada | CA$494.70 Million |
|
Daesung Hi-Tech Co. Ltd.
KQ:129920
|
Korea | ₩130.51 Billion |
|
Prestige Biologics Co. Ltd.
KQ:334970
|
Korea | ₩147.13 Billion |
|
MAGELLANIC CLOUD LTD
NSE:MCLOUD
|
India | ₹4.53 Billion |
|
Enertork Ltd
KQ:019990
|
Korea | ₩8.34 Billion |
|
Bound and Beyond PCL
BK:BEYOND
|
Thailand | ฿6.75 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Alvotech Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alvotech Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alvotech Warrant (2020–2024)
The table below shows the annual total liabilities of Alvotech Warrant from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.63 Billion | -13.20% |
| 2023-12-31 | $1.88 Billion | +35.16% |
| 2022-12-31 | $1.39 Billion | +89.87% |
| 2021-12-31 | $733.59 Million | -45.32% |
| 2020-12-31 | $1.34 Billion | -- |